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ABSTRACT 
 
We report a case of a 13-year-old girl with soft tissue sarcoma of the hand, which 
showed muscle and neuroectodermal immunophenotypes. Molecular studies were 
performed on RNA collected from fine-needle aspiration (FNA) cytology and peripheral 
blood samples by nested reverse transcriptase—polymerase chain reaction (RT-PCR) 
and Southern blot analysis. This biphenotypic tumor showed simultaneous expression of 
EWS-FLI1 and PAX3-FKHR transcripts, specific of Ewing family tumors and alveolar 
rhabdomyosarcoma, respectively. Although childhood sarcomas with simultaneous 
muscle and neural differentiation have been described to have EWS-FLI1 transcripts, 
there are no reports of tumors with both transcripts. Cytological specimens are a good 
source of RNA for molecular studies.  
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INTRODUCTION 
 
Small round cell tumors of childhood remain a diagnostic challenge to the surgical 
pathologist because they share several morphological features and are often difficult to 
distinguish from each other. Because effective therapeutic protocols are available, an 
accurate diagnosis is needed to institute appropriate therapy and predict prognosis. 
Consistent cytogenetic alterations have been identified in several members of this 
family, including alveolar rhabdomyosarcoma, Ewing's sarcoma/peripheral 
neuroectodermal tumor (PNET), and desmoplastic small round cell tumor.1 Recently, 
these chromosomal translocations have been characterized at the molecular level and 
found to result in PAX3-FKHR or PAX7-FKHR chimeric genes in alveolar 
rhabdomyosarcoma,2 EWS-FLI1 and EWS-ERG gene fusions in Ewing's sarcoma/ 
PNET,3 and EWS-WT1 gene fusions in desmoplastic small round cell tumor (DSRCT)4 
Chimeric transcripts and gene fusions specific for each translocation can be detected in 
clinical samples by reverse transcriptase-polymerase chain reaction (RT-PCR) and 
fluorescent in situ hybridization (FISH), and are proving to be a reliable and very useful 
diagnostic technique in the small round cell tumor family.1,5 
 
In this case study, we apply these molecular assays to detect chimeric transcripts in 
cytological specimens and peripheral blood samples in a sarcoma with neuroectodermal 
and muscle differentiation. 
 
 
 
CASE REPORT 
 
A 13-year-old girl developed a painful soft tissue mass in the hypothenar region of the 
left hand. A magnetic resonance imaging (MRI) scan showed a poorly circumscribed 
mass, 2 cm in diameter, without bone involvement. An open biopsy was performed. It 
disclosed (Fig 1A) an undifferentiated solid tumor made up of strands of small cells 
with hyperchromatic nuclei and scant cytoplasm, with material that tested positively 
with periodic acid-Schiff (PAS). The patient was referred to our hospital under the 
diagnosis of extraskeletal Ewing's sarcoma. 
 
Once admitted in our hospital, a left axillary mass was detected. FNAs were performed 
in both the axilla and the left hand mass. They showed the same cytological picture, 
including small cells with hyperchromatic nuclei, sometimes eccentric, finely stippled 
chromatin, occasional nucleoli, and a scant eosinophilic cytoplasm with a small number 
of multinucleated cells were seen. An immunohistochemical study was performed on 
the FNA smears of both locations with antibodies for pan-cytokeratins, vimentin, 
desmin, S-100 protein, NSE, and O13. Cytoplasmic immunoreactivity was detected for 
vimentin, S-100 protein, NSE, O13 (Fig 1B), and desmin (Fig 1C). 
 
A treatment program following the protocol for highgrade sarcoma, including 
radiotherapy and high-dose chemotherapy, was administered. Two months later, the 
axillary mass was resected. It corresponded to a lymph node in which necrotic tumor 
nests were seen in a fibrotic background. A small number of viable tumor cells was seen 
with features similar to those in previous samples (Fig 1D). The patient was discharged 
in good status and is currently finishing the treatment protocol with no gross evidence 
of disease. 
MOLECULAR STUDIES 
  
Available samples for molecular studies include in chronological order: FNAs of the 
left hand mass and lymph node, lymph node excision, and four peripheral blood 
samples (PBS). The first was taken 2 weeks after the FNAs, and the remaining samples 
on a monthly basis. 
 
RNA extraction was performed immediately after the samples were taken with a 
modified guanidine isothiocyanate method, using the reagent TRIZOL (Gibco BRL). 
Search for chimeric transcripta was then performed by nested RT-PCR using 1 µg of 
total RNA as template and a GeneAmp RNA-PCR kit (Perkin-Elmer, Roche Molecular 
Systems, Branchburg, NJ) using the manufacturer's recommendations. Reverse 
transcription included an incubation period of 45 minutes at 42°C with random 
hexamers, followed by a 5-minute period at 99°C to denature the enzyme. PCR was 
then performed with an initial denaturation step of 95°C for 2 minutes, followed by 35 
cycles including a denaturation step at 94°C for 30 seconds, annealing at 66°C (68°C 
for the second round) for 30 seconds, and extension at 72°C for 60 seconds, with 7 
minutes of extension after the completion of the last cycle. A second round of 
amplification was performed in PBS. One fifth of the initial PCR product was amplified 
with a second set of specific internal primers. All PCR products were identified by 2% 
agarose gel electrophoresis and ethidium bromide staining, and then blotted into nylon 
membranes (Hybond+; Nycomed Amersham, Buckinghamshire, United Kingdom), and 
detected with internal probes labeled with chemoluminiscence (Nycomed Amersham). 
Specific primers and probes were used to amplify EWS-FLI1, EWS-ERG, PAX3-
FKHR, and EWS-WT1 and have been reported elsewhere.5,6 
 
EWS-FLI1 chimeric transcripts were detected in FNA but not in PBS. The length of the 
amplified product was constant (Fig 2). Sequencing of the RT-PCR product revealed an 
in-frame fusion of EWS exon 7 to FLIl exon 6, 329 base pairs in length. PAX3-FKHR 
chimeric transcripts (Fig 3) were present in the FNAs performed on the hand mass and 
on the axillary lymph node. They were not present, however, in the lymph node 
excision, 2 months later. EWS-ERG and EWS-WT1 transcripts were not found in any 
sample. 
 
 
 
DISCUSSION 
 
Malignant ectomesenchymomas are sarcomas where areas of neural and muscle 
differentiation are seen. Its primitive variants are composed of undifferentiated cells, 
resembling peripheral neuroepithelioma in some areas and alveolar rhabdomyosarcoma 
in others.7 Our results show a soft tissue tumor in which a double differentiation 
occurred. Immunohistochemical studies support both neuroectodermal and muscle 
differentiation. Moreover, simultaneous expression of EWS-FLI1 and PAX3-FKHR 
fusion transcripts could be shown in this tumor. Those gene fusions are considered 
specific for Ewing family tumors and alveolar rhabdomyosarcomas, respectively. 
Reports in which simultaneous investigation of several chimeric transcripts have been 
performed in small round cell tumors have shown a high correlation between 
histopathological entities and chimeric transcripts.4,5
 
EWS-FLI1 chimeric transcripts have been found in undifferentiated tumors that have 
morphology that is not consistent with ES/PNET, such as the cases reported by Thorner 
et al8 or an intraabdominal small round cell tumor with morphological features of a 
DSRCT.9 None of these studies, however, report the simultaneous finding of two 
chimeric transcripts in a given tumor. EWS-FLI1 transcripts were also reported in a 
series of childhood malignant ectomesenchymomas.10 The authors described six 
biphenotypic sarcomas with both neural and muscle differentiation appearing in soft 
tissues of the chest, the extremities, or retroperitoneum in patients between the ages of 5 
months and 25 years. Interestingly, all these tumors expressed EWS-FLI1 transcripts 
identical to those of the Ewing family of tumors. None of the cases expressed any other 
transcript, including PAX3-FKHR. In another study, however, one of two 
ectomesenchymomas studied showed the PAX3-FKHR fusion gene, which is associated 
with alveolar rhabdomyosarcomas, without evidente of EWS-FLI1 transcripts.11 A 
primitive ectomesenchymoma cell fine has been reported to have the t(11;22) (q24;q12) 
associated with the Ewing family of tumors and another rearrangement involving the 
band 13q14, one of the breakpoints of the t(2;13) (q35; q14) translocation of alveolar 
rhabdomyosarcoma, which was not present.12 Our case is unique for being a primitive 
malignant ectomesenchymoma expressing both transcripts. 
 
FNA has been used in small round cell childhood tumors to obtain material suitable to 
perform cytogenetic studies,13 but karyotypes are laborious and often unsuccessful. As 
far as we know, this is the second report in which EWS-FLI1 transcripts have been 
found on cytological specimens,13 and the first in which PAX3-FKHR fusions are 
detected in FNA material. Our study indicates that material obtained from FNAs, if 
immediately processed, is probably an excellent source of RNA for molecular studies. 
RT-PCR is sensitive enough to detect chimeric transcripts in small samples of aspirated 
tissue. 
 
The high sensitivity of RT-PCR permits the detection of fusion RNAs in peripheral 
blood samples, a promising assay to detect circulating tumor cells and minimal residual 
disease in undifferentiated sarcomas of childhood. It is being used in patients with 
Ewing family tumors6 and alveolar rhabdomyosarcomas14 as a possible means to 
monitor therapy. In our case, it allowed us to monitor the presence of EWS-FLI1 
transcripts in the patient while she was undergoing treatment in which all PBS are 
negative for transcripts. However, the possible prognostic value of chimeric RNA 
detection in childhood sarcomas is still unclear. 
 
The expression of two transcripts seems to be an exceptional feature in childhood 
tumors. Two possible explanations include primitive cells capable of differentiating 
simultaneously along two different pathways, or one of these two transcripts could be a 
secondary genetic alteration on an otherwise conventional alveolar rhabdomyosarcoma 
or Ewing family tumor. Tumors with divergent differentiation such as desmoplastic 
small round cell tumor are a good example of the first possibility, and a challenge to 
tumor classification.5 Because secondary molecular features in pediatric tumors have to 
be further described, the second possibility cannot be discarded. Regardless of etiology, 
this case has shown that neither morphology or our current molecular knowledge are 
sufficient to classify rare cases of childhood solid tumors. 
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NOTE ADDED IN PROOF  
 
Two months after finishing therapy the patient presented progression involving lung and 
multiple bone foci. PBS at this time were positive for EWS-FLI1 transcripts. The 
patient died of disease 4 months after completion of therapy. 
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Figure 1. (A) Primary tumor. Strands of small cells with scanty cytoplasm and 
hyperchromatic nuclei (H&E stain; original magnification ×100). (B) FNA of the 
axillary mass showing intense membrane immunoreactivity for O13 (Streptavidine 
biotin peroxidase counterstained with hematoxylin; original magnification ×100). (C) 
FNA of the axillary mass; tumor ceils show cytoplasmic immunoreactivity for desmin 
(Streptavidine biotin peroxidase counterstained with hematoxylin; original 
magnification ×150). (D) Axillary mass resection. Only a few tumor nests remain after 
treatment in an otherwise necrotic lymph node (H&E stain; original magnification × 
100). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Detection of EWS-FLI1 transcripts by RT-PCR and Southern blot analysis on 
several patient samples. Expected size of the transcript is 329 bp. Lane 1, FNA of the 
hand; lane 2, FNA of the axillary mass; lanes 3-5, Peripheral blood samples taken 2 
weeks, 2 months, and 3 months after resection of the axillary mass, respectively; lane 6, 
positive control. 
 
 
 
 
 
 
Figure 3. Detection of PAX3-FKHR transcripts (409 bp) by RT-PCR. Lane 1, Ewing's 
sarcoma cell line; lane 2, resection of the axillary mass; lane 3, FNA of the axillary 
mass. 
 
 
 
 
 
 
 
